Group-based and Dual-task Focused Otago Exercises in Geriatric Individuals With Kinesiophobia

August 28, 2026 updated by: ebrar atak, Istanbul Medipol University Hospital

Investigation of the Effects of Group-Based and Dual-Task Focused Otago Exercises on Kinesiophobia, Musculoskeletal System and Psychosocial Status in Geriatric Individuals With Kinesiophobia

The aim of our study was to investigate the effects of group-based and dual-task focused otago exercises on kinesiophobia, musculoskeletal system and psychosocial status in geriatric individuals with kinesiophobia. In the study : 1. Do group-based and dual-task focused otago exercises have an effect on kinesiophobia in geriatric individuals with kinesiophobia? 2. Do group-based and dual-task focused otago exercises have an effect on the musculoskeletal system in geriatric individuals with kinesiophobia? 3. Do group-based and dual-task focused otago exercises have an effect on the psychosocial status of geriatric individuals with kinesiophobia? 4. Do group-based and dual-task focused otago exercises have an effect on cognitive function in geriatric individuals with kinesiophobia? The questions were answered.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Our study was conducted as a cross-controlled study on 20 geriatric individuals. The study lasted 12 weeks. The participants in the study were given group otago exercises for 4 weeks, face to face once a week for 30 minutes, and remotely monitored twice a week with handouts containing the exercises. They were asked to walk normally for 30 minutes on 2 days a week. Then, they entered a 4-week washout period. After the washout period, the participants in the study were given group otago exercises for 4 weeks, face to face for 30 minutes, and remotely monitored twice a week with handouts containing the exercises. They were asked to walk normally for 30 minutes on 2 days a week. Before starting the study, participants were given a demographic information form, Tampa Kinesiophobia Scale for kinesiophobia, Berg Balance Scale for balance assessment, Short Form Geriatric Depression Scale for psychosocial status, 5-times sit-to-stand test to assess fall risk and lower extremity muscle strength, Timed Up and Go test to assess mobility, and Mini Mental State Test and Montreal Cognitive Assessment Test to assess cognitive function. These tests were repeated at the end of the first 4 sessions and the last 4 sessions, and pre- and post-test values were measured.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Individuals aged 65 and over
  • Participants who can read and write in Turkish
  • Participants who scored 38 or higher on the Tampa Kinesiophobia Scale
  • Participants who received 24 points or more from the Mini Mental State Test
  • Participating in the study voluntarily
  • Individuals who do not have any disability such as vision, hearing, limb loss, etc.
  • Participants who can walk independently

Exclusion Criteria:

  • Medication status that increases the risk of falls (determined based on information from nursing home nurses and physiotherapists).
  • Individuals who are bedridden or wheelchair bound
  • Individuals with diagnosed mental or psychological problems (The individual's inability to perceive the scales to be applied)
  • Individuals with diagnosed serious neurological or orthopedic problems
  • Individuals with diagnosed serious pulmonary or cardiac disease
  • Individuals with uncontrolled hypertension or diabetes
  • Those with a history of syncope or vertigo attacks in the last 4 weeks

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Other: Otago Exercise Group
Participants in the study were given group otago exercises for 4 weeks, face to face, once a week for 30 minutes. They were also given brochures containing otago exercises twice a week and followed up remotely. They were asked to walk normally for 30 minutes, 2 days a week. Then they entered a 4-week cleansing period.
Other: Otago Exercise
Group-based otago exercises were performed for 4 weeks. They were also given a brochure containing otago exercises twice a week and applied individually and followed remotely. They were asked to walk normally for 30 minutes twice a week. They then entered a 4-week washout period.
Experimental: Dual Task Focused Otago Exercise Group
After a 4-week washout period, participants in the study were given group-based otago exercises and dual-task exercises once a week for 4 weeks. They were given a brochure containing otago exercises including dual-task exercises twice a week and were applied individually and monitored remotely. They were asked to walk normally 2 days a week.
Other: Dual Task Focused Otago Exercise
After a 4-week washout period, face-to-face group-based and dual-task focused otago exercises were applied once a week for 4 weeks. Participants were given a brochure containing otago exercises including dual-task exercises twice a week and applied individually and monitored remotely. They were asked to walk normally for 30 minutes twice a week.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Tampa Kinesiophobia Scale
Time Frame: Duration of change in 4 week
It is a 17-question scale measuring fear of movement/re-injury.
Duration of change in 4 week
Berg Balance Scale
Time Frame: Duration of change in 4 week
It is a scale that includes 14 different types of activities aimed at questioning dynamic and static balance.
Duration of change in 4 week
Geriatric Depression Scale Short Form
Time Frame: Duration of change in 4 week
It is a scale consisting of 15 questions that determines the level of depression in geriatric individuals.
Duration of change in 4 week
5 times sit and stand test
Time Frame: Duration of change in 4 week
Used to assess fall risk and lower extremity muscle strength.
Duration of change in 4 week
Mini Mental Status Test
Time Frame: Duration of change in 4 week
It is a scale used to assess cognitive function.
Duration of change in 4 week
Montreal Cognitive Assessment Test
Time Frame: Duration of change in 4 week
It is a scale used to identify individuals with mild cognitive impairment and to distinguish them from healthy geriatric individuals.
Duration of change in 4 week
Timed Up and Go Test
Time Frame: Duration of change in 4 week
It is a scale used to assess mobility in geriatric individuals.
Duration of change in 4 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul Medipol University Hospital

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Istanbul Gedik University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 15, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 3, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 8, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 27, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 27, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 29, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 1, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 28, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • GroupDualTaskOtagoExercise

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

It will be evaluated if the researchers are contacted via their e-mail addresses.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings